A matrix metalloproteinase inhibitor to treat unresectable cholangiocarcinoma

Matrix metalloproteinases (MMPs) are implicated in tumour invasion and metastasis. We report the first use of an MMP inhibitor to treat unresectable cholangiocarcinoma. Four men with stage IV cholangiocarcinoma received oral Marimastat (10mg bd) indefinitely following relief of obstructive jaundice....

Full description

Saved in:
Bibliographic Details
Published in:HPB (Oxford, England) England), 2005-12, Vol.7 (4), p.289-291
Main Authors: French, J.J., Midwinter, M.J., Bennett, M.K., Manas, D.M., Charnley, R.M.
Format: Article
Language:English
Subjects:
Cholangiocarcinoma
marimastat
matrix metalloproteinase inhibitor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Matrix metalloproteinases (MMPs) are implicated in tumour invasion and metastasis. We report the first use of an MMP inhibitor to treat unresectable cholangiocarcinoma. Four men with stage IV cholangiocarcinoma received oral Marimastat (10mg bd) indefinitely following relief of obstructive jaundice. Monthly measurements of the tumour marker CA 19‐9 were used as an indicator of disease response and activity. CA 19‐9 levels dropped sharply and stayed low in the two patients who appeared to respond. Mean survival of the four patients was 21.5 months (range 4–48 months). Side effects were well tolerated. A more extensive and detailed examination of MMP inhibitors to treat cholangiocarcinoma is indicated.
ISSN:1365-182X
1477-2574
DOI:10.1080/13651820510042246a